Sort
82,697 grants matching “vaccine development”
Alabama-Clinical Trials Unit
$3,475,698Michael S. Saag · University Of Alabama At Birmingham · U01 · FY2009 · AI
Leadership for HIV/AIDS Clinical Trials Networks; Microbicide Trials Network
$3,475,582Barbra A Richardson · Fred Hutchinson Cancer Research Center · U01 · FY2010 · AI
Evolution and Durability of Human T and B Cell Responses
$3,474,901Frances E. Lund · University Of Alabama At Birmingham · U19 · FY2024 · AI
Evolution and Durability of Human T and B Cell Responses
$3,474,901Frances E. Lund · University Of Alabama At Birmingham · U19 · FY2025 · AI
Center/Coordination, Analysis and Management/MACS
$3,473,155Gypsyamber D'souza · Johns Hopkins University · UM1 · FY2016 · AI
BAA-NIH-NIAID-NCRR-DMID-03-036
$3,470,129Andrew A Lackner · Tulane University Of Louisiana · UC6 · FY2006 · AI
Center of Excellence for Encephalitic Alphavirus Therapeutics
$3,469,631Colleen B Jonsson · University Of Tennessee Health Sci Ctr · U19 · FY2020 · AI
Novel Ad/MVA and Ad/Protein HIV-1 Vaccines
$3,469,355Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2016 · AI
Novel Ad/MVA and Ad/Protein HIV-1 Vaccines
$3,468,248Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2013 · AI
Epigenomic analysis of primary immune cells from young and old animals
$3,467,735Myong-Hee Sung · National Institute On Aging · ZIA · FY2021 · AG
The University of North Carolina Center for AIDS Research
$3,466,431Ronald I Swanstrom · Univ Of North Carolina Chapel Hill · P30 · FY2023 · AI
Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose
$3,466,385Marco Pravetoni · University Of Washington · UH3 · FY2024 · DA
IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) - DMID
$3,466,221Kevin Urdahl · Seattle Children'S Hospital · N01 · FY2022 · AI
Task B06: Development and refinement of non-human primate models for medical countermeasure evaluation of BSL-4 viruses
$3,465,763David Beasley · University Of Texas Med Br Galveston · N01 · FY2018 · AI
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AIDS
$3,465,506Jay A Berzofsky · Division Of Clinical Sciences - Nci · ZIA · FY2012 · CA
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders
$3,465,155Richard Childs · Heart, Lung, And Blood Institute · Z01 · FY2007 · HL
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
$3,465,000Adriana H Tremoulet · University Of California, San Diego · P50 · FY2024 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
$3,465,000Adriana H Tremoulet · University Of California, San Diego · P50 · FY2024 · HD
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AIDS
$3,464,609Jay A Berzofsky · Division Of Clinical Sciences - Nci · ZIA · FY2014 · CA
Center for Human Immunology
$3,460,631Yasmine Belkaid · National Institute Of Allergy And Infectious Diseases · ZIC · FY2020 · AI
MANUFACTURE OF CLINICAL GRADE EPSTEIN-BARR VIRUS VACCINE
$3,460,074Midwest Research Institute · N02 · FY2025 · CA
VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGED
$3,457,959Rafi Ahmed · Emory University · U19 · FY2006 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis
$3,457,326Jerrold J. Ellner · Rbhs-New Jersey Medical School · U19 · FY2020 · AI
University of Pittsburgh Clinical Trials Unit
$3,455,746John W Mellors · University Of Pittsburgh At Pittsburgh · U01 · FY2009 · AI
Animal Medicine COVID Support
$3,453,487Mario Roederer · National Institute Of Allergy And Infectious Diseases · ZIG · FY2023 · AI